Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 498 of 6351
-
Less fluid, fewer complications? trial tests new strategy in liver transplants
Disease control Recruiting nowThe goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Ancient herb ashwagandha put to the test against asthma inflammation
Disease control CompletedThis randomized, double-blind, placebo-controlled study evaluated Withania somnifera root powder as a complementary therapy in adults with moderate-to-severe persistent asthma receiving standard asthma treatment. Participants were assigned to standard treatment alone, standard tr…
Sponsor: Aligarh Muslim University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis is a single-arm, open-label, multicenter Phase II clinical study designed to enroll 65 subjects with relapsed or refractory follicular lymphoma (EZH2 wild-type). The study procedures include a pre-screening phase, screening phase, treatment phase, and follow-up phase.Eligib…
Phase 2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingTo apply Ivarmacitinib for the prevention of acute graft-versus-host disease (aGVHD) in HLA haploidentical transplantation, the incidence of grade II-IV aGVHD after prevention, the incidence of primary graft failure, the rate of GVHD-free relapse-free survival (GRFS) (12 months),…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New oral drug shows promise against deadly lassa fever in west africa trial
Disease control PausedThis multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa. The study is conducted within the INTEGRATE platform an…
Phase 2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New Clot-Busting devices aim to save limbs and lives
Disease control Recruiting nowThe study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
Sponsor: Imperative Care, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New pill aims to strengthen hearts in genetic cardiomyopathy
Disease control Recruiting nowThe Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are…
Phase 2/3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug shrinks lung tumors before surgery in early trial
Disease control Recruiting nowThe purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug ICP-332 aims to soothe stubborn hives when antihistamines fail
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Phase 2/3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to shrink spleen in bone marrow cancer
Disease control Recruiting nowThis trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the cont…
Phase 3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New transplant recipe targets tough leukemia
Disease control Recruiting nowThis is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) i…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New bladder cancer cocktail aims to outdo chemo
Disease control Recruiting nowThe study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for small cell lung cancer: immunotherapy after surgery
Disease control Recruiting nowThis is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Phase 2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental T-Cell combo targets Hard-to-Treat leukemia
Disease control Recruiting nowThe goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatme…
Phase 1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough esophageal cancer: targeted drug trial launches
Disease control Recruiting nowThe Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemoth…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Balloon pump in heart vein may limit damage after heart attack
Disease control Not yet recruitingThis study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of the coronary sinus balloon pump (manufactured by Shanghai MicroPort Rotapace Medical Technology Co., Ltd.) as an adjunctive therapy during percutaneous c…
Sponsor: Shanghai MicroPort Rhythm MedTech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could an allergy drug tame COPD Flare-Ups?
Disease control Recruiting nowThis research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat melanoma
Disease control Recruiting nowThis is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participati…
Phase 2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for fertility: drug may reverse early menopause in autoimmune patients
Disease control Recruiting nowSeveral autoimmune diseases such as Addison's disease are associated with failing ovarian function, known as premature ovarian insufficiency (POI), which can lead to early menopause and reduced fertility.The underlying cause of POI in these women is considered to be an immunologi…
Phase 3 • Sponsor: Angelica Lindén Hirschberg • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Home visits by midwives may boost breastfeeding and sleep in new moms
Symptom relief CompletedThis randomized controlled trial evaluated whether a structured, midwife-led home-based postpartum follow-up program could improve breastfeeding self-efficacy, postpartum sleep quality, and maternal attachment among postpartum women. A total of 98 women were randomly assigned in …
Sponsor: Serap Öner • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC